Survival Analysis of Hepatosplenic T Cell Lymphoma: A Population-Based Study Using SEER

Purpose: Hepatosplenic T cell lymphoma (HSTCL) is a rare tumor that lacks data to guide management decisions. To shed light on the nature and therapy of the entity, we conducted this study. Patients and Methods: We retrospectively reviewed patients diagnosed with HSTCL between 1975 and 2016 in the Surveillance, Epidemiology, and End Results (SEER) database to analyze the clinical characteristics and survival outcome compared with PTCL-NOS and ALK+ ALCL. Results: A total of 123 HSTCLs were included in the analysis. Most patients were aged <= 60 years (81.3%) and had a male predominance (69.1%). Organs with lymphoma infiltration of HSTCL were more common in the spleen (98.4%). The 1-year, 3-year, and 5-year overall survival (OS) rates in the entire HSTCL cohort were 56.9% (95% CI, 47.5-66.3%), 37.6% (95% CI, 28.0-47.2%), and 31.6.0% (95% CI, 22.2-41.0%), respectively. The overall survival (OS) of HSTCL patients was similar to that of PTCL-NOS patients (P = 0.128) but worse than that of patients with ALK+ ALCL (P < 0.001). The disease-specific survival (DSS) of HSTCL patients was worse than that of PTCL-NOS and ALK+ ALCL patients (P < 0.05). The same tendency was found in the matched data set. Cox regression analyses indicated that the use of chemotherapy combined with topical treatment may improve the survival of patients with HSTCL. Conclusion: A higher proportion of young patients and a strong male predominance were found in HSTCL. Chemotherapy combined with topical treatment may be an optional regimen. Further studies are needed to intensify efforts in dealing with this rare but unfavorable disease.

Automated summary

This study retrospectively reviewed 123 patients with HSTCL diagnosed between 1975 and 2016 in the SEER database, and found that young patients and a strong male predominance were more common in HSTCL. The overall survival of HSTCL patients was similar to PTCL-NOS patients, but worse than ALK+ ALCL patients, and chemotherapy combined with topical treatment may improve survival rates. Further studies are needed to better understand and treat this rare and unfavorable disease.